针对单克隆抗体的CGRP通过减轻神经炎症来缓解西斯普拉丁诱导的神经病痛
Shun Xie1,2,3, Zhenfang Gao3, Jiale Zhang2
1Navy Clinical College, The Fifth School of Clinical Medicine, Anhui Medical University, Hefei, Anhui Province, 230032, China.
Neurotoxicity research
|January 9, 2024
概括
使用单克隆抗体阻断素基因相关 (CGRP),通过减少神经炎症,有效缓解化疗诱导的神经病痛 (CIPN). 这种方法显示出作为CIPN治疗策略的希望,而不会影响抗瘤疗效.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 化疗诱导的神经病痛 (CIPN) 是癌症治疗的削弱副作用,限制了治疗疗效.
- 目前管理CIPN的策略是不够的.
- 素基因相关 (CGRP) 涉及到各种疼痛病理.
研究的目的:
- 在CIPN.的小鼠模型中研究阻断CGRP的治疗潜力.
- 阐明CGRP为CIPN贡献的基本机制.
主要方法:
- 建立了一个西斯普拉丁诱导的CIPN小鼠模型.
- 评估疼痛过敏性使用·弗雷的头发和尾部动测试.
- 量化CGRP和激活的天体细胞水平通过西方斑点和免疫光学.
- 使用RT-qPCR测量了炎症性细胞因子表达 (IL-6,IL-1β,NLRP3).
主要成果:
- 西斯普拉丁治疗显著增加了脊髓CGRP表达和天体细胞激活.
- 使用抗CGRP单克隆抗体 (ZR8 mAb) 的预处理降低了机械和热过敏.
- ZR8 mAb减弱的西斯普拉丁诱导的神经炎症,降低IL-6,IL-1β和NLRP3水平.
- 在携带瘤的小鼠中,ZR8 mAb并没有阻碍西斯丁的抗瘤作用.
结论:
- 通过单克隆抗体治疗中和CGRP有效地减轻了CIPN.
- 该机制涉及神经炎症的减弱.
- CGRP代表了一种有前途的治疗点,用于治疗化疗引起的神经病痛.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
279
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
279
01:25Analgesia and Pain Management
625
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
625
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
01:44Nociception
27.9K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
27.9K
01:12GPCR Desensitization
6.0K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.0K